Jean-Pierre Bizzari , , M.D. ,

Dr. Bizzari brings extensive experience in oncology drug development. He was Executive Vice President and Global Head of Oncology at Celgene Corporation, responsible for Celgene’s clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan where he oversaw the development and approval of a number of leading oncology products, including REVLIMID® (lenalidomide), VIDAZA®(azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). In addition, he was Chairman of Celgene’s hematology oncology development committee and a member of the company’s management committee. Prior to Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek® (rasburicase). Prior to that he was Vice President, Clinical Development Oncology for Sanofi-Synthelabo and had previously held the same role for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France’s National Cancer Institute and a member of the Transgene board of directors. He is a Doctor of Medicine, a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Dr. Bizzari serves on the Compensation Committee.

Bernadette Connaughton , ,

Ms. Connaughton brings more than 30 years of global strategic, commercial and biopharmaceutical industry expertise. She has spent has spent her career at Bristol-Myers Squibb, building a consistent track record of achieving sales growth, improving profitability and transforming operational models. She most recently served as president Intercontinental, including China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi-year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo®, Yervoy®, Sprycel®, Daklinza® and Orencia®. She has held other senior leadership positions at Bristol-Myers Squibb, including president, European Markets, Canada and Australia; president, Intercontinental; and president, Japan, Pacific Rim, Australia and Canada; senior vice president, Cardiovascular and Metabolic Business Unit, U.S.; and senior vice president, Primary Care Marketing, U.S. Ms. Connaughton was a member of the board of directors of Visterra, Inc., a private clinical stage biotechnology company recently acquired by Otsuka. She also previously served on the European Federation of Pharmaceutical Industry Association, Patient Access and European Markets Committees. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.

James M. Daly , ,

Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses. Over the course of his career, he has built market-leading global franchises across multiple therapeutic categories, with a particular focus in oncology. Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his time, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth. Prior to Incyte, Daly was Senior Vice President of North America Commercial Operations, Global Marketing and Commercial Development for Amgen, with P&L responsibility for all U.S. and Canadian businesses. Daly also served as Vice President and General Manager for Amgen’s Oncology Business Unit. His teams at Amgen were responsible for numerous successful product launches, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Mr. Daly began his career in the pharmaceutical industry at GlaxoSmithKline where he held positions of increasing responsibility over a 16-year period, including Senior Vice President and General Manager of the company’s Respiratory and Anti-infective Business Unit, where he led the U.S. launch of Advair®, and also served as the Senior Vice President of U.S. Marketing. He earned a Bachelor of Science degree in Pharmacy and Master of Business Administration from the State University of New York at Buffalo. Mr. Daly serves on the Nominating and Corporate Governance Committee.

Jeffrey W. Henderson , ,

Mr. Henderson is an Advisory Director to Berkshire Partners, LLC and brings nearly 30 years of financial, commercial and pharmaceutical industry expertise to the board, most recently serving for almost 10 years as chief financial officer of $100-billion health care products and services company, Cardinal Health. Mr. Henderson served as CFO of Cardinal Health from 2005 until the end of 2014, playing a key role in the company’s growth and transformation. During his tenure, the company acquired more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographies and market segments. In addition to his financial responsibilities, Mr. Henderson managed commercial operations in China and Canada. Prior to Cardinal Health, Mr. Henderson was president and general manager of Eli Lilly Canada Inc. and vice president and corporate controller of Eli Lilly & Co. He joined Lilly in 1998 as vice president and corporate treasurer. His prior experience included 10 years at General Motors Corp., where he served in managerial posts in Great Britain, Singapore, New York and Canada. He received his Bachelor of Science degree in electrical engineering from Kettering University, Flint, Mich., and his Master of Business Administration degree from Harvard Graduate School of Business Administration. Mr. Henderson is also Non-Executive Chairman of Qualcomm, Inc., and on the board of directors of Fibrogen, Inc., and Affordable Care, Inc. He serves on the Halozyme Compensation Committee and is the Chair of the Audit Committee.

Kenneth J. Kelley , ,

Mr. Kelley brings over 30 years of entrepreneurial, venture capital, operational and technical biotechnology experience to Halozyme. Mr. Kelley currently serves on the Board of Trustees for the Sabin Vaccine Institute, and was previously on the Board of Directors of privately held PaxVax, Inc., and Jan Medical, Inc. Mr. Kelley is a 2015 Advanced Leadership Initiative (ALI) Fellow at Harvard University focused global health. In 2007 Mr. Kelley founded PaxVax, Inc. and from 2008 until May 2015, Mr. Kelley served as the Chief Executive Officer. From April 2002 through June 2004, Mr. Kelley was a General Partner at Latterell Venture Partners, where he made investments in biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in January 1994 and over eight years served as CEO, Director and Chairman of the Board of Directors. Earlier, Mr. Kelley was an associate at Institutional Venture Partners (IVP), where he participated in the financing of twenty biotech and medical companies, fifteen of which became public companies. Prior to IVP, he was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in biochemical sciences from Harvard University. Mr. Kelley serves on the Audit Committee and as the Chair of the Nominating and Corporate Governance Committee.

Connie L. Matsui , , , Chairman of the Board

Ms. Matsui brings over 16 years of general management experience in the biotechnology industry. She retired from Biogen Idec Inc. in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. She joined IDEC in 1992 and held the positions of Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab (tradenames: Rituxan®, MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards and served as National President/Board Chair of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University. She serves as the Chair of the Board of Directors and as the Chair of the Compensation Committee.

Matthew L. Posard , ,

Mr. Posard has served as President and Chief Commercial Officer of GenePeaks, Inc., a computational genomics company, Executive Vice President, Chief Commercial Officer of Trovagene, where he oversaw sales, marketing, client services, market and business development, and Senior Vice President and General Manager of Illumina’s New Emerging Opportunity Business, where he oversaw the development and transfer of Illumina technology into new markets. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina’s successful commercial entry into the life science sequencing market. Prior to joining Illumina, Mr. Posard held various positions in strategic and product marketing at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. Previously, he oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company’s BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter. He serves on the boards of DermTech, SlipChip Corporation and Omicia. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego. He is a member of the Audit Committee and Nominating and Corporate Governance Committees.

Helen Torley , , M.B. Ch. B., M.R.C.P. ,

Dr. Helen Torley joined Halozyme in January 2014 as President and Chief Executive Officer, and a member of Halozyme’s Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis ®, Prolia®, Sensipar®, and Miacalcin®. Dr. Torley previously served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals overseeing the collaboration with Bayer on Nexavar® and Stivarga ® and the US launch of Kyprolis®. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 14 years in management positions at Amgen, serving as General Manager of both the U.S. Nephrology Business Unit and the U.S. Bone Health Business Unit. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow, and is a Member of the Royal College of Physicians (M.R.C.P). She is a member of the Health Section Governing Board of BIO, the biotechnology innovation organization, and chair of BIO’s Workforce Development, Diversity and Inclusion committee.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok